Colossal Biosciences is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Ben Lamm argues Colossal's platform — genome engineering at scale, full DNA synthesis, and artificial wombs — has planetary-scale applications across invasive species control, human healthcare, and lab-grown materials, making it vastly undervalued despite $635M raised.